International
The Morning Science

What science found today

‹
 

Research

Immune infiltrate predicts response to αPD1/αCTLA4 but not αPD1 and distinguishes programs of primary resistance in metastatic melanoma

Science · By Amy Y. Huang, Kelly P. Burke, Marc C. Glettig, Ryan Porter, Peter Fatouros, Jonathan M. Li, Lynn Meiger, Valeria Rosado, Shuyun Xu, Jiekun Yang, Emily Robitschek, Natalie Vokes, Cora Ricker, Giuseppe Tarantino, Jiajia Chen, Tyler J. Aprati, Yiwen He, Cassia Wang, Doris Fu, Li-Lun Ho, Kyriakitsa Galani, Gordon J. Freeman, Elizabeth I. Buchbinder, F. Stephen Hodi, Christine G. Lian, Manolis Kellis, Genevieve M. Boland, Arlene H. Sharpe & David Liu ·

The Brief

  • A Science Advances study finds that the immune infiltrate in metastatic melanoma predicts response to combined anti-PD1 and anti-CTLA4 checkpoint blockade.
  • The immune infiltrate does not predict response to anti-PD1 alone.
  • The study distinguishes programs of primary resistance in metastatic melanoma.

Why it matters

It suggests that tumour immune infiltrate may help identify which metastatic melanoma patients are likely to respond to combined checkpoint blockade, a question that bears on treatment choice.

Who’s affected

  • oncologists and melanoma researchers
  • cancer immunology researchers

Science Advances, Volume 12, Issue 47 , November 2026.

Timeline

  1. Published in Science Advances, volume 12, issue 47

  2. science.org

    Immune infiltrate predicts response to αPD1/αCTLA4 but not αPD1 and distinguishes programs of primary resistance in metastatic melanoma

How do you feel about this?

0 Comments

    Immune infiltrate predicts response to αPD1/αCTLA4 but not αPD1 and distinguishes programs of primary resistance in metastatic melanoma – The Morning Science